Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (4232)	2/28/2000 11:18:00 PM
From: rkrw	Read Replies (1) \| Respond to of 10280

Sepracor holds less than 18% of Versicor. Sepracor doesn't call the shots, but Tim Barberich does sit on their board as one member amongst nine. Versicor would be a very attractive IPO candidate in this market. Two drugs in the clinic and major partnerships with Novartis and PNU, they also have the magic word, "gene" they could parlay. $1B market cap wouldn't be out of the question in this frenzy (imo). Versicor is on Sepracor's books as a $2M investment, could equate to >$100M if and when they do IPO.